1,120 results on '"Izumi, Tohru"'
Search Results
2. Severe platelet transfusion refractoriness due to anti-HPA-5a antibody during induction chemotherapy for acute promyelocytic leukemia
3. Overlapping states of AWGS muscle dysfunction and inverse feasibility of ADL recovery by rehabilitation in older inpatients
4. A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma
5. Vincristine therapy for severe and refractory immune thrombocytopenia following COVID-19 vaccination
6. Characteristics of Elderly Patients with Heart Failure and Impact on Activities of Daily Living: A Registry Report from Super-Aged Society
7. A phase II Japanese trial of 90-minute rituximab infusion for untreated B-cell lymphoma.
8. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial
9. Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma
10. Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7
11. Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR
12. A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma
13. Comparison of the effects of tolvaptan and furosemide on renal water and sodium excretion in patients with heart failure and advanced chronic kidney disease: a subanalysis of the K-STAR study
14. Data from Myeloma Cells Are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide
15. Supplementary Data from Myeloma Cells Are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide
16. Clinical features and predictors of patients with critical limb ischemia who responded to autologous mononuclear cell transplantation for therapeutic angiogenesis
17. Complementary Role of Arm Circumference to Body Mass Index in Risk Stratification in Heart Failure
18. Quadriceps Strength as a Predictor of Mortality in Coronary Artery Disease
19. The baseline speed of 10-m gait predicts ambulatory discharge for hospitalized frail elderly after DOPPO rehabilitation
20. Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan
21. Net Clinical Benefit of Rivaroxaban versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation: A Subgroup Analysis of J-ROCKET AF
22. Rivaroxaban versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation in Relation to the CHADS2 Score: A Subgroup Analysis of the J-ROCKET AF Trial
23. Rivaroxaban versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation for the Secondary Prevention of Stroke: A Subgroup Analysis of J-ROCKET AF
24. CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21)
25. Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma
26. Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan
27. A national survey on myocarditis associated with influenza H1N1pdm2009 in the pandemic and postpandemic season in Japan
28. Fulminant Myocarditis—From Lethal Disease to Survival
29. Myosin Autoreactive T Cells And Autoimmune Myocarditis. Lessons from the Disease Caused by Cardiac Myosin Peptide CM2
30. Animal Models of Autoimmune Myocarditis
31. Enhancement of Early Diastolic Filling Provoked by Dobutamine Infusion in Dilated Cardiomyopathy
32. Usefulness of ST elevation score by using vector-projected virtual 187-channel ECG for risk stratification in patients with Brugada-type ECG pattern
33. Effect of persistent activation of phosphoinositide 3-kinase on heart
34. Long-term observation of fibrillation cycle length in patients under angiotensin II receptor blocker therapy for chronic atrial fibrillation
35. Baseline cardiac magnetic resonance imaging versus baseline endomyocardial biopsy for the prediction of left ventricular reverse remodeling and prognosis in response to therapy in patients with idiopathic dilated cardiomyopathy
36. Do Ketone Bodies Contribute to Protection against Damage Caused by Bothmyocardial Ischemia and Reperfusion Injury?
37. The Effects of Depression on the Course of Functional Limitations in Patients With Chronic Heart Failure
38. Effect of Ethanol on Allylamine-Induced Subendocardial Fibrosis
39. A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma
40. Vincristine therapy for severe and refractory immune thrombocytopenia following COVID-19 vaccination
41. Therapeutic strategy using extracorporeal life support, including appropriate indication, management, limitation and timing of switch to ventricular assist device in patients with acute myocardial infarction
42. Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study
43. Clinical significance of heart rate during acute decompensated heart failure to predict left ventricular reverse remodeling and prognosis in response to therapies in nonischemic dilated cardiomyopathy
44. Cardiac Contractile Proteins and Autoimmune Myocarditis
45. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma
46. Preventive Effect of Amiodarone on VT/VF Events in ICD Patients with Structural Heart Diseases
47. Attenuating Effects of Anti-Arrhythmic Agents on Changes in Fibrillation Cycle Length in Very Early Phase Paroxysmal Atrial Fibrillation —Spectral Analysis of Fibrillation Waves in Surface ECG—
48. Phase III Clinical Pharmacology Study of Tolvaptan
49. Efficacy and Safety of Tolvaptan in Heart Failure Patients with Volume Overload Despite the Standard Treatment with Conventional Diuretics: A Phase III, Randomized, Double-blind, Placebo-controlled Study (QUEST Study)
50. Effects of Tolvaptan on Volume Overload in Japanese Patients with Heart Failure: Results of a Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.